AXL kinase as a novel target for cancer therapy

Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balazs Halmos

Research output: Contribution to journalArticlepeer-review

140 Scopus citations


The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.

Original languageEnglish (US)
Pages (from-to)9546-9563
Number of pages18
Issue number20
StatePublished - 2014
Externally publishedYes


  • Axl
  • Lung cancer
  • Receptor tyrosine kinase
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'AXL kinase as a novel target for cancer therapy'. Together they form a unique fingerprint.

Cite this